BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (AMEX: AKN) today announced that it has signed a Definitive Agreement with Azad Pharma, a privately-held pharmaceutical company located in Toffen, Switzerland, to develop and supply Latanoprost, Bimatoprost and Travoprost, three ophthalmic ANDA drug products for the treatment of glaucoma. The total United States market size for these three products is $870M, according to 2006 IMS data.
